menu
    • menu

    Company profile for EyePoint Pharmaceuticals

    NEW Drugs in Dev: 6
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    EyePoint PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    480 Pleasant Street Suite B300 Watertown MA 02472 United States
    Telephone
    Telephone
    1-833-393-7646
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://eyepointpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/eyepointpharmaceuticals/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/EyePointPharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arvo

    Arvo

    Not Confirmed

    envelop Contact Supplier

    Arvo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    EyePoint to Report Q1 2026 Results on May 6, 2026
    EyePoint to Report Q1 2026 Results on May 6, 2026

    29 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/29/3283609/0/en/eyepoint-to-report-first-quarter-2026-financial-results-on-may-6-2026.html

    GLOBENEWSWIRE
    29 Apr 2026
    Share Share
    Eyepoint Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)
    Eyepoint Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)

    16 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/16/3275791/0/en/EyePoint-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    16 Apr 2026
    Share Share
    Eyepoint Sues Ocular For Defamation In Retina Drug Race
    Eyepoint Sues Ocular For Defamation In Retina Drug Race

    23 Mar 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/eyepoint-lawsuit-accuses-ocular-malicious-defamation-campaign-retina-drug-race

    FIERCE PHARMA
    23 Mar 2026
    Share Share
    EyePoint Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)
    EyePoint Discloses Inducement Grants Per NASDAQ LR 5635(C)(4)

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256114/0/en/EyePoint-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Eyepoint Unveils 2025 Financials, Corporate Updates
    Eyepoint Unveils 2025 Financials, Corporate Updates

    04 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/04/3249208/0/en/EyePoint-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Highlights-Recent-Corporate-Developments.html

    GLOBENEWSWIRE
    04 Mar 2026
    Share Share
    Eyepoint To Release 2025 Financial Results On March 4, 2026
    Eyepoint To Release 2025 Financial Results On March 4, 2026

    25 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/25/3244449/0/en/EyePoint-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-March-4-2026.html

    GLOBENEWSWIRE
    25 Feb 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search